Quick answers

What is BPC-157 and what is it used for in research?
BPC-157 is classified within the Healing & Recovery group. Pentadecapeptide derived from human gastric-juice BPC. In animal studies, BPC-157 has been shown to upregulate VEGF and modulate the NO pathway, and is being researched for its potential to promote tendon, ligament, and gut-mucosal repair. Not approved for human therapeutic use in any jurisdiction; sold for laboratory research only. Research applications focus on the pathways outlined below. All references on this page describe published research only, BPC-157 is supplied for in-vitro and laboratory use, not for human consumption.
How does BPC-157 work?
Primary mechanism: Synthetic pentadecapeptide; studied for tendon-to-bone healing applications in preclinical (rodent) models. Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for BPC-157 remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical BPC-157 research dose?
Published research protocols for BPC-157 describe per-dose ranges of 250–500 mcg / day, with a weekly total near 1.75–3.5 mg, administered 1–2× daily sc. Typical cycle: 4–6 weeks. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy BPC-157 in Thailand?
BPC-157 is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk, no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can BPC-157 be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

What is BPC-157?

BPC-157 is a research peptide in the Healing & Recovery class. Synthetic pentadecapeptide; studied for tendon-to-bone healing applications in preclinical (rodent) models. It is studied at per-dose ranges of 250–500 mcg / day (1.75–3.5 mg weekly), administered 1–2× daily sc over cycles of 4–6 weeks. Supplied in Thailand by Thailand Peptides, Bangkok-based, research use only.

Pentadecapeptide derived from human gastric-juice BPC. In animal studies, BPC-157 has been shown to upregulate VEGF and modulate the NO pathway, and is being researched for its potential to promote tendon, ligament, and gut-mucosal repair. Not approved for human therapeutic use in any jurisdiction; sold for laboratory research only.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does BPC-157 work?

Research suggests BPC-157 upregulates VEGFR2 expression in endothelial cells and modulates the endothelial nitric oxide synthase (eNOS) / NO pathway, which together are being researched for their potential to promote angiogenesis. In animal studies of tendon fibroblasts, BPC-157 has been shown to activate focal adhesion kinase (FAK)–paxillin signalling that may underlie cell outgrowth and migration. Preclinical research has explored additional dopaminergic, serotonergic, and GABAergic modulation that may contribute to gut–brain axis effects. Not approved for human therapeutic use in any jurisdiction; sold for laboratory research only.

Receptor binding affinity and post-receptor signalling for BPC-157 remain areas of active investigation; several proposed effects within the Healing & Recovery class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

BPC-157 pharmacokinetics

Half-life
Short systemic half-life (~minutes to hours post-SC); gastric-stable oral activity described in rodent models.
Bioavailability
Oral and SC routes both used in research protocols; survives gastric juice in preclinical work.
Route of administration
Subcutaneous injection near injury site is the most common research route; intraperitoneal and oral also reported.
Metabolic clearance
Primarily renal clearance of unchanged peptide and fragments in preclinical PK studies.

BPC-157 research timeline

  1. 2011 Sikiric review, gastric pentadecapeptide BPC 157 in gastrointestinal research (Curr Pharm Des).
  2. 2011 Chang et al., BPC 157 promotes tendon outgrowth, cell survival, and migration (J Appl Physiol).
  3. 2015 Huang et al., BPC-157 enhances alkali-burn wound healing via angiogenesis and proliferation (Drug Des Devel Ther).
  4. 2018 Seiwerth et al., review of BPC 157 and standard angiogenic growth factors (Curr Pharm Des).

BPC-157 dosage & protocol

Reference protocol for BPC-157 (research context only, drawn from published literature):

  • Per dose: 250–500 mcg / day
  • Weekly total: 1.75–3.5 mg
  • Frequency: 1–2× daily SC
  • Cycle: 4–6 weeks

BPC-157 injection & handling

Reconstitution
Typical research protocol: reconstitute a 5 mg vial in 2–3 mL bacteriostatic water, yielding 1.67–2.5 mg/mL.
Storage
Lyophilised powder stable at −20 °C; reconstituted solution refrigerated at 2–8 °C and used within 2–4 weeks in published protocols.
Sites used in the research literature
Subcutaneous administration to the abdominal wall or near the injured tissue is the most common site in the primary literature.

Handling notes reflect methods used in published research protocols, not medical dosing guidance.

Order BPC-157
Ready to order? WhatsApp the Bangkok research desk, pricing and availability confirmed within the chat.
Ask about BPC-157 ≥98% HPLC purity · supplier COA on file · Bangkok-based

Stacking BPC-157

Commonly referenced pairing with BPC-157: TB-500. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a BPC-157 stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

Active malignancy, undiagnosed tumours. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

Research summaries

Further reading

Citations

  1. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011. PMID: 21548867
  2. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. PMID: 21030672
  3. Huang T, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015. PMID: 25995620
  4. Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors. Curr Pharm Des. 2018. PMID: 29998800

References curated from PubMed. Additional literature summarised in the Thailand Peptides research library.